Advertisement

Comparison of Clinical Trials in Acute Myelogenous Leukaemia by use of a Mathematical Model

  • R. R. P. Jackson
  • L. J. Moullin
  • W. Gregory
  • R. Bell
  • J. M. A. Whitehouse
  • T. A. Lister
Part of the Medizinische Informatik und Statistik book series (MEDINFO, volume 26)

Summary

We describe the development and application to clinical trials of a mathematical model of patient behaviour in acute myelogenous leukamia (AML). Observed patient behaviour in a trial can be compared with predictions made by a model derived from another set of trial data and deviations from these predictions identified and assessed. This form of analysis is applicable to trials in progress, allowing early detection of trends and differences.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    PETO, R., 1978: Clinical Trial Methodology. Biomedicine 28, 24-36.Google Scholar
  2. 2.
    MEIER, P., 1975: Statistics and Medical Experimentation. Biometrics 31, 511-529.CrossRefzbMATHGoogle Scholar
  3. 3.
    TUKEY, J.W.: Where do we go from here? Journal of the American Statistical Assocn. 55, 80-93.Google Scholar
  4. 4.
    GEHAN, E.A., FREIREICH, E.J., 1974: Non-Randomised Controls in Cancer Clinical Trials. The New England Journal of Medicine. 290, 198-203.CrossRefGoogle Scholar
  5. 5.
    BLACK, SIR DOUGLAS: The Paradox of Medical Care. Journal of the Royal College of Physicians of London. 13, 2, 57-65.Google Scholar
  6. 6.
    COONBERG, L., 1979: Do retrospective controls make clinical trials “inherently fallacious?” British Medical Journal 2365-2366.Google Scholar
  7. 7.
    ASPDEN, P., JACKSON, R.R.P., WHITEHOUSE, J.M.A., 1976: A systems approach to the evaluation of clinical trials in a specialist oncology centre. Proc. NATO Conf. Systems Science in Health Care, Paris.Google Scholar
  8. 8.
    JACKSON, R.R.P., ASPDEN, P., 1979: Treatment Evaluation --A Modelling Approach with Application to Acute Myeloid Leukaemia. J. Opl. Res. Soc. Vol. 30, 1, pp 11-22.zbMATHGoogle Scholar
  9. 9.
    LISTER, T.A., OLIVER, R.T.D., WHITEHOUSE, J.M.A., BELL, R., JOHNSON, S.A.N., WRIGLEY, P.F.M., FORD, J.M., CULLEN, M.H., GREGORY, W.M., PAXTON, A.M., MALPAS, J.S., Chemotherapy and Immunotherapy for Acute Myelogenous Leukaemia. Accepted by Cancer, 1979.Google Scholar
  10. 10.
    CROWTHER, D., POWLES, R.L., BATEMAN, C.J.T., BEARD, M.E.J., GANCI, C.K., WRIGLEY, P.F.M., MALPAS, J.S., HAMILTON FAIRLEY, G., BODLEY SCOTT, SIR RONALD, 1973: The Management of Adult Acute Myelogenous Leukaemia. British Medical Journal 20 January 1973, pp 131-137.Google Scholar
  11. 11.
    CROWTHER, D., BEARD. M.E.J., BATEMAN, C.J.T., SEWELL, R.L., 1975: Factors influencing prognosis in Adults with Acute Myelogenous Leukaemia. British J. Cancer, 32, 456-464.CrossRefGoogle Scholar
  12. 12.
    KEATING, M.J., BODEY, G.P., McCREDIE, K.B., FREIREICH, E.J., 1979s Five Year Survival and Remission Duration in Adult Acute Myelogenous Leukaemia (AML). Proc. A.S.C.O., C-517, p 416.Google Scholar
  13. 13.
    MOULD, R.F., 1979: Clinical Trial Design in Cancer. Clin. Radiol. 30, 371-381.CrossRefGoogle Scholar
  14. 14.
    PETO et al, 1976/77: Design & Analysis of Randomised Clinical Trials requiring Prolonged Observations of each patient. I. Introduction and design. British Journal of Cancer, 34, 585-612. Analysis and Examples, British Journal of Cancer, 35, 1-39.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • R. R. P. Jackson
    • 1
  • L. J. Moullin
    • 2
  • W. Gregory
    • 1
  • R. Bell
    • 3
  • J. M. A. Whitehouse
    • 4
  • T. A. Lister
    • 3
  1. 1.Research Centre for the Mathematical Modelling of Clinical TrialsUniversity of WarwickCoventryUK
  2. 2.National Coal BoardLondonUK
  3. 3.ICRF Department of Medical OncologySt. Bartholomew’s HospitalLondonUK
  4. 4.CRC Wessex Medical Oncology Unit CF93Southampton General HospitalSouthamptonUK

Personalised recommendations